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ABSTRACT
Introduction: Ventilator-associated pneumonia (VAP)
is a common and potentially lethal problem among
mechanically ventilated neonates in neonatal intensive
care units (NICUs). The main pathogenic bacteria of
VAP in NICUs are Gram-negative pathogens, which
show a general decline in sensitivities to commonly
used antibiotics, but their true prevalence is not known.
Methods and analysis: We aim to provide a
systematic review of studies measuring the prevalence
of Gram-negative bacteria in VAP in NICUs. We will
search PubMed, SCOPUS, EMBASE and the ISI Web of
Science, as well as the Google Scholar search engine
with no restriction on language. Full copies of articles
will be identified by a defined search strategy and will be
considered for inclusion against predefined criteria.
Study selection and data extraction will be performed by
2 independent reviewers. Statistical analysis will include
the identification of data sources and documentation of
estimates, as well as the application of the random-
effects and fixed-effects meta-analysis models. This will
allow us to aggregate prevalence estimates and account
for between-study variability in calculating the overall
pooled estimates and 95% CI for the prevalence of
Gram-negative bacteria in VAP in NICUs. Heterogeneity
will be evaluated using the I2 and χ2 statistical tests to
determine the extent of variation in effect estimates due
to heterogeneity rather than chance. Publication bias
and data synthesis will be assessed by funnel plots and
Begg’s and Egger’s tests using STATA software V.13.
This systematic review protocol was prepared according
to the Preferred Reporting Items for Systematic reviews
and Meta-Analyses Protocols (PRISMA-P) 2015
Statement.
Ethics and dissemination: No ethical issues are
predicted. These findings will be published in a peer-
reviewed journal and presented at national and
international conferences.
Trial registration number: CRD42016036048.
INTRODUCTION
Ventilator-associate pneumonia (VAP) is
pneumonia in mechanically ventilated
patients, and develops after the patient has
been placed on mechanical ventilation (MV)
for at least 48 hours.1–4 MV is an essential
feature of modern neonatal intensive care
unit (NICU). Unfortunately, it is associated
with a substantial risk of VAP.5 Tracheal intub-
ation is associated with a 3–21-fold risk of
developing pneumonia.6 VAP is the second
most common hospital-acquired infection
among paediatric and NICU patients.3 4 The
range of VAP incidence density rates in chil-
dren and neonates is large. Rates have been
reported as low as 1/1000 ventilator days and
as high as 63/1000 ventilator days. The inci-
dence follows a geographical distribution
and depends on the type of hospital and the
country’s income level.7
VAP is associated with increased duration
of hospital stay resulting in high morbidity
and mortality among NICU patients.8–10
Surveillance studies of nosocomial infections
in NICU patients indicate that pneumonia
comprises 6.8–32.3% of nosocomial infec-
tions in this setting.11–13
Strengths and limitations of this study
▪ This is the first attempt as a systematic review to
summarise the prevalence of Gram-negative bac-
teria in ventilator-associated pneumonia (VAP) in
neonatal intensive care units (NICUs).
▪ We will include observational studies that used
the US Centers for Disease Control and
Prevention (CDC) and National Healthcare Safety
Network (NHSN) definitions.
▪ The study screening, data extraction and the risk
of bias of the current study will be assessed
independently by two researchers.
▪ This study could potentially help policymakers
and guideline developers in the management of
neonates with VAP in NICUs.
▪ This review is restricted to a neonatal population
(<1 year of age).
▪ This review will be limited by the quality and het-
erogeneity of the primary studies.
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Many factors predispose infants to acquiring VAP;
infants mechanically ventilated in the NICU are at a par-
ticularly high risk of developing VAP because of poor
host factors, severe underlying diseases, prolonged use
of MV, inadequate pulmonary hygiene, and extensive
use of invasive devices and procedures.14–17 In addition,
poor nutritional state and hypoalbuminaemia contribute
to the development of VAP in neonates.6 The aetio-
logical agent of VAP may differ according to the length
of hospital stay, comorbid conditions and exposition of
antimicrobials.18 Since many premature babies require
MV, VAP has become a major challenge in NICUs. VAP
has a large inﬂuence on neonatal survival, morbidity,
hospital costs and duration of NICU stay.4 19 20
Neonates have unique characteristics predisposing
them to nosocomial infections. These patients’ imma-
ture immune systems place them at an increased risk of
infection.21 Skin and mucous membranes are more per-
meable and are less effective barriers.22 The pathogen-
esis of VAP involves two processes: bacterial colonisation
of the aerodigestive tract and aspiration of contaminated
oral secretions into the lower airways, as endotracheal
tubes used to ventilate neonates are not cuffed.23
The clinical criteria for the diagnosis of VAP have
been established by the National Healthcare Safety
Network (NHSN) and the US Centers for Disease
Control and Prevention (CDC). However, it should be
noted that no gold standards currently exist for the diag-
nosis of VAP in neonates.6–10 Microbial diagnosis of VAP
is based on the culture of samples obtained from the
lower respiratory tract by tracheal aspirate, which is con-
sidered a less-invasive method with an acceptable diag-
nostic accuracy.24 Understanding the microbiology of
VAP is critical for choosing an empirical antibiotic
therapy; however, lack of a speciﬁc deﬁnition and difﬁ-
culties obtaining uncontaminated samples of the lower
respiratory airway render microbiological diagnosis and
aetiological treatment extremely difﬁcult.25
The most commonly isolated causative organisms are
Gram-negative bacteria which show a general decline in
sensitivities to commonly used antibiotics.26 Aerobic
Gram-negative bacilli account for more than 60% of
VAP cases. However, some investigators have reported
that Gram-positive bacteria have become increasingly
more common, with Staphylococcus aureus being the pre-
dominant isolate.27 The most common pathogens iso-
lated in the neonatal population are Pseudomonas
aeruginosa and S. aureus.7 28 29 However, isolation of
other microorganisms such as Klebsiella pneumoniae and
Escherichia coli has also been reported. Isolated
Acinetobacter strains are practically resistant to all gener-
ally prescribed antibiotics.2 9 28 30–33
Prevalence studies of Gram-negative bacteria in VAP in
NICUs are even sparser. Badr et al34 revealed that
Gram-negative bacteria were isolated from the majority
of patients with VAP (68.6%), with Klebsiella predominat-
ing the positive culture (34.3%). Koksal and colleagues
found that Acinobacter was the predominating causative
agent, whereas Petdachai reported that Pseudomonas was
the most common organism isolated.35 36
The prevalence of Gram-negative bacteria in develop-
ing VAP in NICUs has been reported, and estimates
range from 60% to 97% with Pseudomonas, Klebsiella and
Acinobacter organisms predominating the positive
cultures.2 9 26 28 30 31 34
It is controversial to what extent we can rely on epi-
demiological results for the prevalence of Gram-negative
bacteria in VAP in NICUs. This calls for caution when
the epidemiological data for the prevalence are inter-
preted, and indicate that it is important to attempt to
understand what underpins the variation. Accurate esti-
mates of the true prevalence of a causative organism are
of value in planning diagnostic and intervention
services.
It is possible that study design, the deﬁnition of VAP
and differences related to the included participants and
sample collection methods explain the inconsistencies
in the currently available studies.
We propose to conduct a systematic review and
meta-analysis to investigate the prevalence of Gram-
negative bacteria in VAP in NICUs.
Objectives
The primary objective of this review is to conduct a sys-
tematic review and meta-analysis to estimate the preva-
lence of Gram-negative bacteria in VAP in NICUs. The
secondary objectives of this review are: (1) to ﬁnd the
most commonly isolated causative Gram-negative bac-
teria in VAP in NICUs and its antibiotic susceptibility
pattern, (2) to estimate pooled mean VAP rate (VAPs
per 1000 mechanical ventilator days) and (3) to evaluate
the risk factors of VAP in NICUs. This review will com-
plement the ﬁndings of existing published reviews.7 10 25
Review questions
This systematic review will be guided by the following
research questions:
1. What is the prevalence of Gram-negative bacteria in
VAP in NICUs in different countries?
2. What are the most commonly isolated causative
Gram-negative bacteria in VAP in NICUs?
3. What are the antibiotic susceptibility patterns of iso-
lated causative Gram-negative bacteria in VAP in
NICUs?
METHODS
The Preferred Reporting Items for Systematic reviews
and Meta-Analyses for Protocols 2015 (PRISMA-P 2015)
have been used for preparing and reporting the proto-
col of this systematic review.37 In addition, the PRISMA
flow diagram will be employed to describe the ﬂow of
information through the different phases of this system-
atic review.38 The protocol of this systematic review has
been registered in PROSPERO 2016 (registration
number CRD42016036048).
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Inclusion criteria
Observational studies (cross-sectional, case–control and
cohort) describing the prevalence of Gram-negative bac-
teria in VAP in NICUs will be included. We will consider
published articles in any languages, with full English
abstracts.
Exclusion criteria
1. Duplicate publications of the same material. When
the study has been published in more than one
journal, the most recent and complete version will be
used.
2. Narrative reviews, opinion pieces, letters or any other
publications lacking primary data and/or explicit
method descriptions.
Search methods for identification of studies
Electronic searches
We will search PubMed, SCOPUS, EMBASE and the ISI
Web of Science, as well as the Google Scholar search
engine with no language restrictions until 15 May 2016.
Keywords: Systematic Review, Ventilator Associated
Pneumonia, NICU, Gram Negative bacteria.
PubMed search strategy
MeSH tags were found in PubMed. The details of the
PubMed database search syntax are provided below.
(Prevalence OR incidence OR frequency OR outbreaks
OR occurrence OR epidemiology OR epidemiologic
studies OR ‘population-based’) AND (‘ventilator-associated
pneumonia’ OR pneumonia) AND ‘Gram negative’ AND
(bacteria OR microorganism OR pathogens).
The search syntax will be modiﬁed in other databases.
Other resources
Reference lists of relevant primary studies, reviews and
key journals will be searched for additional studies.
Selecting studies for inclusion
Full-text articles identiﬁed by the search that will poten-
tially meet inclusion criteria based on the title and
abstract will be obtained for data synthesis. Studies will
be screened against predeﬁned inclusion and exclusion
criteria. Two authors will be assigned to evaluate and
appraise the results of the searches, based on the title
and abstract. The reviewers will then either mark the
studies as included or excluded. Once all the studies
have been reviewed independently, the reviewers will
together compare their evaluations; discrepancies will be
discussed and, if necessary, a third reviewer will be called
to resolve any disagreements.
Data extraction and management
A data extraction form will be developed, and study data
will be independently assessed and extracted by two
reviewers (YE and LJ).
The following data will be extracted from all the
included studies:
1. Study characteristics (author, year of publication, lan-
guage of publication, country, study design, setting,
locations, criteria for sample selection and sample
size, diagnostic criteria, outcomes measured, hospital
duration stay, and patient enrolment strategies);
2. Participants’ characteristics (age, gender, ethnicity).
Unavailable information from included studies will be
sought from corresponding authors by email. Eligible
studies will be categorised according to the outcome
data they provide (ie, prevalence, mortality, case fatality)
and the clinical setting in which the participants are
assessed. Any disagreements regarding the inclusion of
studies will be resolved by discussion or by consulting a
third reviewer. A table of all included studies will be
inserted and the reasons for exclusion of studies will be
documented.
Quality appraisal of included studies
The methodological quality of primary studies will be
assessed by a quality assessment tool developed by Hoy
et al39 and adapted by Werfalli et al,40 which will be
applied and adapted, if necessary, to all screened full-
text articles, in order to assess the study quality. The
deﬁned questions will be answered and the score of
each article will be calculated using this assessment tool.
Studies will be graded as low risk, moderate risk and
high risk for scores ≤5, 6–8 and >8, respectively. An
independent investigator will be consulted through dis-
cussion to reach consensus where there is uncertainty or
disagreement between reviewers. An evaluation of the
risk of bias will allow for sensitivity analysis.
Data synthesis
All included studies will be overviewed and presented in
two separate tables. The ﬁrst table will provide details on
study quality according to the mentioned tool. The
other table will include study design, participants and
the characteristics of isolated bacteria.
Our statistical analysis of the primary measures will
include two steps: (1) identiﬁcation of data sources and
documenting estimates, and (2) using a random-effects
and ﬁxed-effects meta-analysis model to aggregate preva-
lence estimates and to account for variability between
studies, by calculating the overall pooled estimate and
the 95% CI.
Initially, the data will be analysed using a narrative
method. Heterogeneity will be evaluated to determine
the extent of variation in effect estimates due to hetero-
geneity rather than chance. The heterogeneity among
the primary studies will be evaluated by the forest plots,
χ2 test (with signiﬁcance deﬁned at the α-level of 10%)
and I2 statistic.
The prevalence of Gram-negative bacteria in VAP in
NICUs from different studies will be pooled through a
meta-analysis using STATA V.13 statistical software (Stata
Corp. 2013. Stata Statistical Software: Release 13. College
Station, Texas, USA: Stata Corp LP).
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Assessment of heterogeneity
The heterogeneity among the included studies will be
assessed using the I2 heterogeneity statistic, reported as a
percentage (%), to determine the extent of variation
among the studies.41 Categories of heterogeneity will be
deﬁned as follows: ≤25% low, 26–50% moderate, 51–
75% substantial and 76–100% as considerable, deﬁned
by Higgins. Forest plots will also be used to further iden-
tify heterogeneity by means of the χ2 test (with signiﬁ-
cance deﬁned at the α-level of 10%) and the I2 statistic
(where ≥50% indicates substantial heterogeneity).
Sensitivity analysis
We will implement sensitivity analyses to explore the
impacts of methodological quality and sample size on the
robustness of review conclusions. Meta-analyses will be
repeated after excluding studies with lower methodo-
logical quality and studies with sample sizes much larger
than those of other studies. Sensitivity analyses will be
reported in a summary table, and reviewed conclusions
will be interpreted by making comparisons between the
two meta-analyses. Any discrepancies or disagreements
will be discussed by the reviewers and, if necessary, they
will call an independent reviewer to provide clariﬁcation.
Subgroup analyses
Subgroup analyses will be conducted according to the
region, gender and isolated Gram-negative bacteria.
Assessment of reporting bias
The publication bias will be assessed by funnel plots (ie,
plots of study results against precision) and Begg’s and
Egger’s tests.
Reporting of this review
We will make use of ﬂow diagrams to summarise the
inclusion criteria and selection process of studies, and
also to detail the reasons for exclusion. This systematic
review will be reported according to the PRISMA 2009
guidelines.37 The search strategy and quality appraisal
tool will also be published as online supplementary
material documents.
Ethics and dissemination
Systematic reviews draw on publicly available data and
therefore do not require formal ethical review. The ﬁnd-
ings of this systematic review will be disseminated
through peer-reviewed journal publications and confer-
ence proceedings.
To the best of our knowledge, there are no systematic
reviews that have speciﬁcally looked at the prevalence of
Gram-negative bacteria in VAP in NICUs. We expect this sys-
tematic review will help policymakers and guideline develo-
pers in the management of neonates with VAP in NICUs.
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